Beckman Coulter Life Sciences announced a strategic partnership with London automation firm Automata to integrate liquid‑handling and cell analysis instruments into Automata’s LINQ AI‑ready automation platform. The collaboration aims to deploy modular, cloud‑orchestrated lab workcells that enable high‑throughput, standardized data generation for AI‑driven discovery workflows. The tie includes Danaher Ventures participating in Automata’s Series C and a board seat, reflecting industrial investors’ interest in closing the loop between laboratory robotics and AI. Automata separately confirmed a $45 million Series C round that will fund scaling of deployments, product development and international expansion. The two announcements together position lab automation vendors and instrument makers to sell integrated, ‘AI‑ready’ platforms to pharma and academic customers wanting reproducible, structured datasets. Sources include corporate releases from Beckman Coulter and Automata; Danaher’s investment underlines how strategic venture participation is being used to accelerate lab automation adoption.